“...an interesting and potentially clinically important finding in the study by de Abajo and colleagues is that the use of RAAS inhibitors compared with other antihypertensive drugs almost halved the risk of adverse outcomes in patients with COVID-19 who had diabetes (adjusted OR 0·53, 95% CI 0·34–0·80).4 Other studies have also suggested that use of RAAS inhibitors might confer protective effects against complications and death in patients with COVID-19 versus other antihypertensive drugs, although these studies were not restricted to patients with diabetes.9, 10
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31131-4/fulltext
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/fulltext
protective effect of RAAS (ace2) inhibitors with Diabetic Covid patients
MedCram Lecture
May 14, 2020
Dr. Roger Seheult
Coronavirus Pandemic Update 70: Glutathione Deficiency, Oxidative Stress, and COVID 19
As many states in the US make arrangements to re-open their economies, Dr. Seheult discusses some recent trends in COVID-19 infections and deaths. Glutathione is a substance produced naturally by the liver- and is also found in vegetables, fruits, and meats. Dr. Seheult discusses some interesting case reports from New York and Russia that suggest glutathione deficiency may be related to COVID-19 severity. More studies are needed to assess if supplementation of NAC and glutathione could aid in the prevention and treatment of COVID-19
https://www.youtube.com/watch?v=OtL0B1bqXak
related:
gut microbiome and the immune system - call for research: